Active substance
Perphenazine
- US FDA 23
- Health Canada 4
- US price lines 4
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PERPHENAZINE | 2MG | tablet · oral | SANDOZ | Prescription | 8 Dec 1988 |
| PERPHENAZINE | 4MG | tablet · oral | SANDOZ | Prescription | 8 Dec 1988 |
| PERPHENAZINE | 8MG; 2MG; 4MG; 16MG | tablet · oral | SANDOZ | Prescription | 8 Dec 1988 |
| PERPHENAZINE | 16MG | tablet · oral | SANDOZ | Prescription | 8 Dec 1988 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | PH HEALTH | Prescription | 31 Dec 1998 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | WILSHIRE PHARMS INC | Prescription | 17 Dec 2015 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | WATSON LABS INC | Prescription | 17 Oct 2016 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | RISING | Prescription | 1 Mar 2019 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | ZYDUS PHARMS | Prescription | 6 Apr 2020 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | SOMERSET THERAPS LLC | Prescription | 18 May 2022 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | MACLEODS PHARMS | Prescription | 6 May 2024 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | JUBILANT GENERICS | Prescription | 18 Mar 2025 |
| TRILAFON | 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 16MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | SCHERING | Discontinued | 27 Feb 1957 |
| TRILAFON | 5MG/ML | injectable · injection | SCHERING | Discontinued | 29 Jan 1958 |
| TRILAFON | 16MG/5ML | concentrate · oral | SCHERING | Discontinued | 12 Dec 1958 |
| PERPHENAZINE | 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ANI PHARMS | Discontinued | 10 Sep 1987 |
| PERPHENAZINE | 16MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ANI PHARMS | Discontinued | 10 Sep 1987 |
| PERPHENAZINE | 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ANI PHARMS | Discontinued | 10 Sep 1987 |
| PERPHENAZINE | 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ANI PHARMS | Discontinued | 10 Sep 1987 |
| PERPHENAZINE | 16MG/5ML | concentrate · oral | PHARM ASSOC | Discontinued | 25 May 2001 |
| PERPHENAZINE | 2MG; 4MG; 8MG; 16MG | tablet · oral | MYLAN | Discontinued | 14 Apr 2017 |
| TRILAFON | 2MG/5ML | syrup · oral | SCHERING | Discontinued | |
| TRILAFON | 8MG | tablet, extended release · oral | SCHERING | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PERPHENAZINE | 00335096 | 16 MG | TABLET · ORAL | AA PHARMA INC |
| PERPHENAZINE | 00335118 | 8 MG | TABLET · ORAL | AA PHARMA INC |
| PERPHENAZINE | 00335126 | 4 MG | TABLET · ORAL | AA PHARMA INC |
| PERPHENAZINE | 00335134 | 2 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PERPHENAZINE 16 MG TABLET | $0.3911 | per EA | 23 Sep 2026 |
| US NADAC | PERPHENAZINE 2 MG TABLET | $0.19667 | per EA | 23 Sep 2026 |
| US NADAC | PERPHENAZINE 4 MG TABLET | $0.16125 | per EA | 23 Sep 2026 |
| US NADAC | PERPHENAZINE 8 MG TABLET | $0.13539 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.